New Treatment Method for SGLT2 Inhibitors and Antihypertensive Agents

This patent pertains to a medication that combines SGLT2 inhibitors and antihypertensive agents, useful in treating hypertension and diabetes. SGLT2 inhibitors lower blood sugar levels and antihypertensive agents lower blood pressure. This provides a treatment method that reduces the risk of cardiovascular events and is applicable to patients with declining renal function.

• Co-usage of SGLT2 inhibitors and antihypertensive agents
• Applicability to patients with renal impairment
• Reduction of cardiovascular event risks

Conventional hypertension treatment often requires a combination of multiple medications, placing a significant burden on patients. Additionally, managing blood sugar levels and blood pressure simultaneously in diabetic patients is challenging, increasing the risk of cardiovascular events. Furthermore, treatment options for patients with declining renal function are limited.

By combining SGLT2 inhibitors and antihypertensive agents, blood sugar levels and blood pressure can be managed simultaneously, reducing the risk of cardiovascular events. Specifically, using certain 1-thio-D-glucitol compounds as SGLT2 inhibitors and renin-angiotensin-aldosterone system inhibitors as antihypertensive agents to provide a treatment method applicable to patients with declining renal function.

• Technology that can manage blood sugar levels and blood pressure simultaneously
• Technology that can reduce the risk of cardiovascular events
• Technology applicable to patients with renal impairment